Novo Nordisk, the maker of Wegovy and Ozempic, told investors this month that its global workforce has shrunk by about 13,000 employees over the past year, falling to roughly 67,000 people. The company disclosed the figure at a Sept. 21 Capital Markets Day, saying that about 9,000 of the reduction came from a restructuring plan it announced a year earlier, while another 4,000 departures disclosed this month reflect attrition, retirements and other exits rather than new layoffs. The update lands as the drugmaker fights to defend the obesity-drug market it helped create against fast-growing competition.
What a 13,000-person workforce drop doesn’t spell out: Novo Nordisk’s own numbers don’t say how many departures left with severance still in place, the gap The Bank Account & Debt Protection Kit’s frozen-account response covers. Look up the frozen-account response before a bill goes unpaid →
What Novo Nordisk disclosed, and when
The 13,000 figure and the drop to roughly 67,000 employees come from Novo Nordisk’s own Capital Markets Day presentation on Sept. 21, as BioSpace’s layoff tracker reported two days later, citing the company’s disclosure directly. CEO Maziar Mike Doustdar used the event to outline the reductions as part of an effort to unify operations and, in his words, “drive more funds into research and development.” The 9,000-position portion of the total traces back to a restructuring Novo Nordisk announced in a Sept. 10, 2025 release, when the company employed 78,400 people across 80 countries and said it would cut about 11.5 percent of that workforce, roughly 5,000 of the reductions concentrated in Denmark, to reach DKK 8 billion in annualized savings by the end of 2026.
The math behind the 13,000
Novo Nordisk’s own accounting splits the year-over-year drop into two pieces, and it drew a deliberate line between them. The first 9,000 positions were the layoffs announced in September 2025; the additional 4,000, revealed only this month, are departures the company says should not be read as a second wave of cuts. “Workforce levels changed for reasons including normal attrition, retirements, voluntary departures, decisions to not backfill roles and other hiring decisions, as well as organizational changes,” the company said, according to BioSpace’s report of the Capital Markets Day remarks. Even with that distinction, the net effect for the roughly 67,000 people still on Novo Nordisk’s payroll is the same: a materially smaller organization than the one that existed a year ago.
The cuts already reached a U.S. plant
Part of the original 9,000-position plan landed inside the United States within days of the announcement. FiercePharma reported that Novo Nordisk filed a state layoff notice cutting 263 positions at its U.S. headquarters in Plainsboro, New Jersey, effective by the end of 2025, tying the cut directly to the same DKK 8 billion, or roughly $1.3 billion, annual savings target the company had just announced. New CEO Doustdar, then six weeks into the job, cited competitive pressure in the obesity-drug market and a falling market capitalization as the backdrop for the decision. NJBIZ’s separate report on the same 263-position cut quoted Doustdar calling the move “the right thing to do for the long-term success of Novo Nordisk.” Those Plainsboro job losses are now nearly a year old, meaning any severance or notice period tied to them has almost certainly already run its course.
Why the obesity-drug leader is still cutting
Novo Nordisk built the modern GLP-1 weight-loss market with Wegovy and Ozempic, but the September 2025 restructuring announcement made clear the company no longer sees its position as secure. Doustdar framed the cuts around agility rather than retreat: “We need a shift in our mindset and approach so we can be faster and more agile,” he said in the company’s own September 2025 announcement, which also said the savings would be reinvested into diabetes and obesity commercial efforts and research aimed at reaching patients the company is not yet treating. A year and roughly 13,000 fewer employees later, that reinvestment case is still the company’s stated justification for a workforce that keeps shrinking rather than stabilizing.
What the disclosure leaves for an affected household to sort out
None of the figures Novo Nordisk has published, not the 78,400 baseline, not the 9,000 planned cuts, not this month’s additional 4,000 departures, address what happens in the months after a paycheck from the company stops. Some of the 4,000 newly disclosed departures were retirements, by the company’s own account, which raises its own transition questions around benefits and timing; others were layoffs whose notice period and any severance are now finite. Federal law does not fill that gap either: as the U.S. Department of Labor states, “there is no requirement in the Fair Labor Standards Act (FLSA) for severance pay,” since “severance pay is a matter of agreement between an employer and an employee.” Whether the exit came a year ago in Plainsboro or is part of this month’s newly disclosed total, the practical risk is the same one any laid-off worker faces once whatever severance was negotiated ends and bills keep coming: a missed payment that turns into a collections call, or a bank account a creditor tries to freeze.
The Gap Between a Severance Check and the Next Paycheck
Novo Nordisk’s own disclosures stop at the size of the workforce reduction, 13,000 fewer people than a year ago, without addressing what any individual departure means for a household’s bills once severance or unemployment benefits run out. That gap, between the last company paycheck and whatever income replaces it, is where a debt collector’s call or a frozen bank account becomes a real risk rather than a hypothetical one.
The Bank Account & Debt Protection Kit lays out the debt-validation steps for handling a collector’s call and the frozen-account response for a bank account a creditor has tried to freeze.
Read the frozen-account response in The Bank Account & Debt Protection Kit.
This article was produced with AI assistance and checked against the primary sources linked above.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
